Intervention with Clarithromycin in Patients with Stable Coronary Heart Disease
Hansen S. · Als-Nielsen B. · Damgaard M. · Helø O.H. · Petersen L. · Jespersen C.M.
The CLARICOR Trial Design
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Background: There is a growing body of evidence linking Chlamydia pneumoniae to the progression of coronary heart disease. Smaller studies have indicated that intervention with macrolide antibiotics might reduce coronary events in patients with cardiovascular diseases. Objective: To describe the design of a large-scale intervention study on the effects of a macrolide antibiotic on coronary events in patients with stable coronary heart disease (documented myocardial infarction and/or angina pectoris). Methods: This study is a double-blind, randomised, placebo-controlled, multicentre study with parallel groups. Patients are randomised to 14 days of treatment with clarithromycin (500 mg, once daily) or matching placebo. The follow-up period is 2 years, and the primary end point is a composite end point of death, non-fatal myocardial infarction or unstable angina pectoris, whichever occurs first. Recruitment began in October 1999 and will be completed in 2000. In total, 4,600 patients will be randomised. Prospectives: The study is powered to detect a reduction in coronary events of 20%. Also, the study will examine the question of whether the presence of a C. pneumoniae antibody titre is associated with a significantly increased risk of future coronary events. Finally, in the case of a significant outcome, it will be possible to test whether the effect is restricted to patients with C. pneumoniae antibodies only, or to a universal effect without any coherence to C. pneumoniae antibodies.
© 2000 S. Karger AG, Basel
- Danesh J, Collins R, Peto R: Chronic infection and coronary heart disease: Is there a link. Lancet 1997;350:430–436.
Leinonen M, Saikku P: Infections and atherosclerosis: Scand Cardiovasc J 2000;34:12–20.
- Metha JL, Saldeen TG, Rand K: Interactive role of infection, inflammation and traditional risk factors in atherosclerosis and coronary artery disease. J Am Coll Cardiol 1998;31:1217–1225.
Maass M, Bartels C, Engel PM, Mamat U, Sievers H-H: Endovascular presence of viable Chlamydia pneumoniae is a common phenomenon in coronary artery disease. J Am Coll Cardiol 1998;318:27–32.
- Mayr M, Metzler B, Kiechl S, Willeit J, Schett G, Xu Q, Wick G: Endothelial cytotoxicity mediated by serum antibodies to heat shock proteins of Escherichia coli and Chlamydia pneumoniae: Immune reactions to heat shock proteins as a possible link between infection and atherosclerosis. Circulation 1999;99:1560–1566.
- Dechend R, Mass M, Gieffers J, Dietz R, Scheidereit C, Leutz A, Gulpa DC: Chlamydia pneumoniae infection of vascular smooth muscle and endothelial cells activates NF-κB and induces tissue factor and PAI-1 expression: A potential link to accelerated arteriosclerosis. Circulation 1999;100:1369–1373.
- Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ: Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromycin in male survivors of myocardial infarction. Circulation 1997;96:404–407.
- Anderson JL, Muhlestein JB, Carlquist J, Allen A, Trehan S, Nielson C, Hall S, Brady J, Egger M, Horne B, Lim T: Randomized secondary prevention trial of azithromycin in patients with coronary artery disease and serological evidence for Chlamydia pneumoniae infection: The Azithromycin in Coronary Artery Disease: Elimination of Myocardial Infection with Chlamydia (ACADEMIC) study. Circulation 1999;99:1540–1547.
- Fagerberg B, Gnarpe J, Gnarpe H, Agewall S, Wikstrand J: Chlamydia pneumoniae but not cytomegalovirus antibodies are associated with future risk of stroke and cardiovascular disease: A prospective study in middle-aged to elderly men with treated hypertension. Stroke 1999;30:299–305.
- Markus HS, Sitzer M, Carrington D, Mendall MA, Steinmetz H: Chlamydia pneumoniae infection and early asymptomatic carotid atherosclerosis. Circulation 1999;100:832–837.
- Wong Y-K, Dawkins K, Ward ME: Circulating Chlamydia pneumoniae DNA as a predictor of coronary artery disease. J Am Coll Cardiol 1999;34:1435–1439.
- Glader CA, Boman J, Saikku P, Stenlund H, Weinehall L, Hallmanns G, Dahlen GH: The proatherogenic properties of lipoprotein(a) may be enhanced through the formation of circulating immune complexes containing Chlamydia pneumoniae-specific antibodies. Eur Heart J 2000;21:639–646.
- Ridker PM, Kundsin RB, Stampfer MJ, Poulin S, Hennekens CH: Prospective study of Chlamydia pneumoniae IgG seropositivity and risk of future myocardial infarction. Circulation 1999;99:1161–1164.
- Ridker PM, Hennekens CH, Buring JE, Kundsin R, Shih J: Baseline IgG antibody titers of Chlamydia pneumoniae, Helicobacter pylori, herpes simplex virus, and cytomegalovirus and the risk for cardiovascular disease in women. Ann Intern Med 1999;131:573–577.
- Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B: Randomised trial of roxithromycin in non-Q-wave coronary syndromes: ROXIS Pilot Study. ROXIS Study Group. Lancet 1997;350:404–407.
- Gurfinkel E, Bozovich G, Beck E, Testa E, Livellara B, Mautner B: Treatment with the antibiotic roxithromycin in patients with acute non-Q-wave coronary syndromes. The final report of the ROXIS Study. Eur Heart J 1999;20:121–127.
- Vaughan CJ, Murphy MB, Buckley BM: Statins do more than just lower cholesterol. Lancet 1996;348:1079–1082.
- Langtry HD, Brogden RN: Clarithromycin. A review of its efficacy in the treatment of respiratory tract infections in immunocompetent patients. Drugs 1997;53:973–1004.
- Seppala H, Nissinen A, Jarvinen H, Huovinen S, Henriksson T, Herva E, Holm SE, Jahkola M, Katila ML, Klaukka T, et al: Resistance to erythromycin in group A streptococci. N Engl J Med 1992;326:292–297.
- Gould IM: A review of the role of antibiotic policies in the control of antibiotic resistance. J Antimicrob Chemother 1999;43:459–465.
- Wang SP, Grayston JT: Immunologic relationship between genital TRIC, lymphogranuloma venereum and related organisms in a new microtiter indirect immunofluorescence test. Am J Ophthalmol 1970;70:367–374.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.